FDA Clears Path for Cheaper Heparin Generics to Hit Market
Published Date: 8/4/2025
Notice
Summary
The FDA says three types of heparin sodium injectable drugs weren’t pulled from the market because of safety or effectiveness problems. This means generic drug makers can now get approval to make and sell their versions, helping keep medicine options open and possibly prices down. Patients and healthcare providers can keep trusting these medicines without worry.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Enables ANDA Approvals Referencing These Heparins
Because of that finding, the FDA can approve abbreviated new drug applications (ANDAs) that refer to these three heparin sodium products under NDA 019042, provided all other legal and regulatory requirements are met. That allows companies seeking generic approval to use these reference products in their ANDA submissions.
FDA Finds Three Heparin Products Intact
The FDA determined that three heparin sodium injectable products under NDA 019042 were not withdrawn from sale for reasons of safety or effectiveness. The products named include: heparin sodium 1,000 units in sodium chloride 0.9% in plastic container (injectable, 200 units/100 mL), heparin sodium 2,000 units in sodium chloride 0.9% in plastic container (injectable, 200 units/100 mL), and heparin sodium 5,000 units in sodium chloride 0.9% in plastic container (injectable, 1,000 units/100 mL).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
Previous / Next Documents
Previous: 2025-14686, Request Notice: Use of Foreign-Built Small Passenger Vessel in United States Coastwise Trade, S/V MORNING STAR
The Maritime Administration is checking if a foreign-built small passenger boat, the S/V MORNING STAR, can be used for trips along the U.S. coast. They want to make sure this won’t hurt American boat builders or businesses using U.S.-made vessels. If you’re involved in coastal boat trade, now’s the time to share your thoughts before a decision is made!
Next: 2025-14693, Combined Notice of Filings
Several natural gas pipeline companies have filed requests to change their rates and agreements starting September 1, 2025. These updates could affect customers and partners by adjusting prices or contract terms. If you want to speak up or get involved, you have until August 11, 2025, at 5 p.m. ET to comment or protest.